IONS earnings call for the period ending September 30, 2019.
News & Analysis: Ionis Pharmaceuticals
A licensing deal gives investors confidence in a turnaround.
Information from competitors and a collaborator sent the high-flying biotech lower.
Fourth-quarter earnings exceed expectations.
The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.
Two news events in one day have the biotech seeing red.
News of a major transaction between these two companies sends their stock prices in opposite directions.
It was a breakout year for the clinical-stage biotech.
Long-awaited trial results point in the right direction for Alnylam and suggest tougher competition for Ionis.
Investors think it's awfully early for sales of this company's first blockbuster to stagnate.
Some downbeat news from a Phase 3 trial overshadowed all the good news that was delivered during the month.